NUTM1 and neoplasm: Many other fusion partners have been identified since, including BRD3, NSD3, ZNF532, ZNF592, and CIC (4–7), leading to the notion that classification, clinical behavior, and therapeutic options may be best defined by the NUTM1 fusion partner rather than by tumor morphology or the immunohistochemical profile (8, 9).